The American President took a big decision. He announced that 100% tariff will be imposed on medicines coming from many countries including India. Meaning that if any medicine goes to America, its price will double. Trump called it a ploy to promote Made in America. But in reality this decision was an economic attack on India’s growing pharma power. But India turned this war not into an economic war but into a game of strategy and transformed disaster into opportunity. The Government of India and the Pharma Industry immediately started work in four directions.
Read this also: Was there a conspiracy to create a rift in Russia-India relations? Russia calls news of selling JF-17 engines to Pakistan ‘baseless’
From accessing new markets to promoting the country’s production. From strengthening the supply chain to strengthening global partners. India rotated its supply line. The ships that used to go to America earlier. The same ships are now heading towards Europe, Africa, Latin America and Russia. Indian companies like Sun Pharma, Doctor Ready’s, Cipla and Lupin will now directlyAfrica,Have gone to supply medicines in Russia and South America. That means India has opened new doors in front of the closed wall of America.
Read this also: France surrounded the ship coming to India carrying 7 lakh 50 thousand barrels of oil, then Russia showed its fierce form.
When America imposed tariff on India,When the trick worked, the rest of the world embraced India. First India’s friend Russia, then Europe and now Africa signed a new deal with India. France, Germany, Brazil, Egypt and Indonesia even said that if medicine is needed then the route will go through New Delhi. Indian pharmaceutical companies increased their capacity.
Read this also: Putin will come in December, how many S-400 will he bring for India?
Dr Reddy’s Laboratories invested ₹565 crore in its wholly owned subsidiary Dr Reddy’s Laboratories LLC, Russia (DRL Russia) and acquired 45.19 per cent equity stake. The transaction is a result of the decision by the Hyderabad-based company’s board to invest up to ₹600 crore in the Russian arm in November 2024. The investment was completed on cash payment on July 25, 2025, BSE was informed. The funds invested by the company in DRL Russia will be used for working capital requirements.